430 E. 29th street
About Prevail Therapeutics
Prevail Therapeutics is a biotechnology company focused on developing novel biologic therapies for Parkinson’s Disease and other neurodegenerative diseases. Prevail was launched in 2017 by The Silverstein Foundation for Parkinson’s with GBA, REGENXBIO, and OrbiMed, and is headquartered in New York, NY.
Founders: Silverstein Foundation for Parkinson’s with GBA, REGENXBIO, OrbiMed, and Asa Abeliovich
1 article with Prevail Therapeutics
Cardurion Pharmaceuticals, today announced that it has expanded its leadership team with the addition of chief operating officer, Rebecca V. Frey, Pharm.D.